Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Type 2, Insulin Resistance, Obesity, Nutritional and Metabolic Disease
Interventions: DASH, Whole-Food, Plant-Based; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Webster, New York

Conditions: Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
Interventions: Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy, Research blood draw; Device · Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Concord, California • Escondido, California • Santa Barbara, California

Conditions: Diabetes Mellitus
Interventions: Arts-Based Storytelling Workshop Series; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years to 25 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
Interventions: Trastuzumab deruxtecan, Trastuzumab, Pertuzumab, Endocrine Therapy, Palbociclib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Columbia, Maryland • Las Vegas, Nevada • Nashville, Tennessee + 2 more

Conditions: Overweight, Obesity, Type 2 Diabetes, Prediabetes
Interventions: Weight loss diet, Weight loss diet plus exercise; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma
Interventions: INO-1400, INO-9012, INO-1401; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more

Conditions: Obesity, Diabetes
Interventions: home-delivered meals, diabetes education for 12 months; Dietary Supplement · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: Faster-acting insulin aspart, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes
Interventions: ATSM Intervention; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pain, Diabetic Neuropathy
Interventions: Neurodex; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 44
States / cities: Mesa, Arizona • Sun City, Arizona • Hot Springs, Arkansas + 39 more

Conditions: Diabetes, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Continuous Glucose Monitoring Sensor, Diabetes Management Instructions; Device · Other
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: FOLFIRINOX, Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil (5-FU), NIS793, Chemoradiation, Capecitabine, Radiation Therapy, Surgery; Drug · Radiation · Procedure
Lead sponsor: Colin D. Weekes, M.D., PhD; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: MK-1403 + additive coformulation, Placebo + additive coformulation; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Anaheim, California • Chula Vista, California • Miami, Florida + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more

Conditions: Diabetes Type 2, Diabetes Mellitus, Obesity
Interventions: Cryoablation of the Vagus Nerve, Lifestyle Intervention; Device · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 22 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Ulcer Healing, Diabetic Foot Ulcer
Interventions: human keratin graft; Device
Lead sponsor: ProgenaCare Global, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Miami, Florida • Frederick, Maryland • Salem, Virginia

Conditions: Type 2 Diabetes
Interventions: Dexcom G6 CGM; Device
Lead sponsor: Blanchard Valley Health System; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Findlay, Ohio

Conditions: Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Follicular Carcinoma, Recurrent Thyroid Gland Papillary Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Follicular Carcinoma AJCC v7, Stage III Thyroid Gland Papillary Carcinoma AJCC v7, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Unresectable Differentiated Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions: Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate, Pembrolizumab; Other · Drug · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 7
States / cities: Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Program ENERGY, comparison; Behavioral · Other
Lead sponsor: Colorado State University; Other
Eligibility: 6 Years to 13 Years
Enrollment: 2,909 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 45 Years to 64 Years
Enrollment: 1,276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 1 Diabetes
Interventions: Dehydroepiandrosterone, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Metastatic Malignant Neoplasm in the Breast, Metastatic Malignant Neoplasm in the Colon, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Rectum, Pancreatic Carcinoma
Interventions: 18F-αvβ6-BP; Drug
Lead sponsor: Julie L. Sutcliffe, Ph.D; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Effects of a Plant-Based Diet on Insulin Requirements and Obesity Markers in Obese Adults With T2DM

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System

Evaluation of Arts-Based Storytelling Program in Adolescents With Diabetes

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

Evaluating the Effects of a Diet and Exercise Program in People With Type 2 Diabetes or Prediabetes: (The SHAPE3 Study)

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes

Reducing Emergency Department Visits and Improving Glucose Control in Uncontrolled Type 2 Diabetes Using CGM Sensors at Hospital Discharge

FOLFIRINOX + NIS793 in Pancreatic Cancer

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Cryovagotomy Diabetes Trial

Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers

Community Glucose Monitoring Project

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Obesity and Diabetes Prevention Through Science Enrichment

Finding Diabetes Mellitus Among Veterans

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide